Bicyclic peptide ligands specific for MT1-MMP

Patent metadata

Field	Value
Publication number	US-12350343-B2
Application number	US-201917309631-A
Country	US
Kind code	B2
Filing date	Dec 13, 2019
Priority date	Dec 13, 2018
Publication date	Jul 8, 2025
Grant date	Jul 8, 2025

Abstract

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP), such as the collagen binding site of MT1-MMP. The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.

First claim

The invention claimed is:

1. A peptide ligand specific for the collagen binding site of MT1-MMP comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a non-aromatic molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold, wherein the peptide ligand comprises an amino acid sequence:
C i -P-F/I/Y-D/S—W-H-T-C ii -L-F-G-D/E-Y-T/S-C iii (SEQ ID NO: 1)
wherein C i , C ii and C iii represent first, second and third cysteine residues, respectively, or a pharmaceutically acceptable salt thereof.

2. The peptide ligand as defined in claim 1 , wherein the peptide ligand comprises an amino acid sequence selected from:

(SEQ ID NO: 2)

CPYSWETCLFGDYRC;

(SEQ ID NO: 3)

CPFDWHTCLFGDYTC;

(SEQ ID NO: 4)

CPFDWHTCLFGEYSC;

(SEQ ID NO: 5)

CPIDWHTCLFGDYTC;

(SEQ ID NO: 6)

CPFSWHTCLFGEYSC:

(SEQ ID NO: 7)

CPFSWHTCLFGDYTC;

(SEQ ID NO: 8)

CPISWHTCLFGDYSC;

and

(SEQ ID NO: 9)

CPYSWHTCLFGDYSC.

or a pharmaceutically acceptable salt thereof.

3. The peptide ligand as defined in claim 1 , wherein the molecular scaffold is TATA.

4. The peptide ligand as defined in claim 3 , wherein the molecular scaffold is TATA and the peptide ligand comprises an amino acid sequence selected from:
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076),
or a pharmaceutically acceptable salt thereof.

5. The peptide ligand as defined in claim 1 , wherein the peptide ligand is a free acid, or a pharmaceutically acceptable salt selected from the sodium, potassium, calcium, and ammonium salt.

6. The peptide ligand as defined in claim 1 , wherein the MT1-MMP is human MT1-MMP.

7. A drug conjugate comprising the peptide ligand as defined in claim 1 , conjugated to one or more effector and/or functional groups, wherein the one or more effector and/or functional groups are one or more cytotoxic agents.

8. The drug conjugate as defined in claim 7 , wherein said cytotoxic agent is selected from MMAE and DM1.

9. A pharmaceutical composition which comprises the peptide ligand of claim 1 , in combination with one or more pharmaceutically acceptable excipients.

10. The pharmaceutical composition as defined in claim 9 , which additionally comprises one or more therapeutic agents.

11. A method for preventing, suppressing or treating a disease or disorder mediated by MT1-MMP in a patient, comprising administering to the patient the drug conjugate as defined in claim 7 .

12. A pharmaceutical composition which comprises the drug conjugate of claim 7 , in combination with one or more pharmaceutically acceptable excipients.

13. The pharmaceutical composition as defined in claim 12 , which additionally comprises one or more therapeutic agents.

14. The peptide ligand as defined in claim 2 , wherein the peptide ligand comprises an amino acid sequence selected from:
A-(SEQ ID NO: 3)-A (BCY1057);
A-(SEQ ID NO: 4)-A (BCY1065);
A-(SEQ ID NO: 5)-A (BCY1067);
A-(SEQ ID NO: 6)-A (BCY1073);
A-(SEQ ID NO: 7)-A (BCY1074);
A-(SEQ ID NO: 8)-A (BCY1075); and
A-(SEQ ID NO: 9)-A (BCY1076),
or a pharmaceutically acceptable salt thereof.

15. A drug conjugate comprising the peptide ligand as defined in claim 1 , conjugated to one or more effector and/or functional groups, wherein each one or more effector and/or functional groups is a metal chelator.

16. The drug conjugate of claim 15 , wherein the metal chelator is complexed to a metal radioisotope.

17. The drug conjugate of claim 16 , wherein the metal radioisotope is selected from 64 Cu, 67 Ga, 68 Ga, 177 Lu, 90 Y, and 213 Bi.

Assignees

• Bicycletx Ltd

Inventors

• Stace Catherine
• Teufel Daniel
• Walker Edward

Classifications

• C07K7/64

  Cyclic peptides containing only normal peptide links · CPC title

• A61K47/552

  one of the codrug's components being an antibiotic · CPC title

• A61K47/6415

  Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins · CPC title

• C12N9/6491

  Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23) · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title